Disse ikke- kliniske forsøg har vist, at dasatinib kan overvinde imatinibresistens, der stammer fra BCR- ABL overekspression, BCR- ABL kinasedomæmemutationer, aktivering af andre signalveje der involverer kinaser, der tilhører SRC- kinasefamilien (LYN, HCK), og multimedicinskresistens genetisk overekspression.
These non-clinical studies show that dasatinib can overcome imatinib resistance resulting from BCR-ABL overexpression, BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multidrug resistance gene overexpression.